{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:02Z","timestamp":1786119242125,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1097\/inf.0b013e318195205e","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T10:30:07Z","timestamp":1242901807000},"page":"385-390","source":"Crossref","is-referenced-by-count":24,"title":["Immunogenicity and Tolerability in Infants of a New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine"],"prefix":"10.1097","volume":"28","author":[{"given":"Sharon H.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana R.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Ypma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"O'Hallahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210202","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/508780","article-title":"Vaccine prevention of meningococcal disease: making slow progress.","volume":"43","author":"Harrison","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R2-5-20210202","first-page":"959","article-title":"Vaccines. 4th ed.","author":"Granoff","year":"2004"},{"key":"R4-5-20210202","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R5-5-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human Immunity to the Meningococcus. I: the role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R6-5-20210202","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/CVI.00102-07","article-title":"Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.","volume":"14","author":"Trotter","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"R7-5-20210202","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway.","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"R8-5-20210202","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile.","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"key":"R9-5-20210202","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"key":"R10-5-20210202","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/ije\/24.5.1050","article-title":"Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.","volume":"24","author":"Noronha","year":"1995","journal-title":"Int J Epidemiol"},{"key":"R11-5-20210202","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Annals"},{"key":"R12-5-20210202","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines: a Randomised Controlled Trial in Chile.","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"R13-5-20210202","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","article-title":"New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.","volume":"177","author":"Martin","year":"1998","journal-title":"J Infect Dis"},{"key":"R14-5-20210202","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.vaccine.2005.01.050","article-title":"New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.","volume":"23","author":"Dyet","year":"2005","journal-title":"Vaccine"},{"key":"R17-5-20210202","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"key":"R18-5-20210202","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/CVI.00167-07","article-title":"Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.","volume":"14","author":"Hosking","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"R19-5-20210202","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.inf.0000258697.05341.2c","article-title":"New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16\u201324 months.","volume":"26","author":"Wong","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R21-5-20210202","article-title":"Report on Maternity. Maternal and Newborn Information 2002.","year":"2004"},{"key":"R22-5-20210202","article-title":"Immunisation Handbook 2006:"},{"key":"R23-5-20210202","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.vaccine.2005.01.070","article-title":"Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials.","volume":"23","author":"Martin","year":"2005","journal-title":"Vaccine"},{"key":"R24-5-20210202","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"R25-5-20210202","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/IAI.62.10.4419-4424.1994","article-title":"Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.","volume":"62","author":"Milagres","year":"1994","journal-title":"Infect Immun"},{"key":"R28-5-20210202","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"R29-5-20210202","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.","volume":"17","author":"Cartwright","year":"1999","journal-title":"Vaccine"},{"key":"R30-5-20210202","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1086\/320993","article-title":"Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory.","volume":"184","author":"de Kleijn","year":"2001","journal-title":"J Infect Dis"},{"key":"R31-5-20210202","first-page":"1221","article-title":"The New Zealand Hepatitis B screening programme: screening coverage and prevalence of chronic hepatitis B infection.","volume":"118","author":"Robinson","year":"2005","journal-title":"NZ Med J"},{"key":"R32-5-20210202","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/00006454-199607000-00006","article-title":"Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age.","volume":"15","author":"Greenberg","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"R33-5-20210202","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0196-6553(89)90213-7","article-title":"Clinical experience with hepatitis B vaccines.","volume":"17","author":"West","year":"1989","journal-title":"Am J Infect Control"},{"issue":"suppl 1","key":"R34-5-20210202","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/0264-410X(93)90154-P","article-title":"Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations.","volume":"11","author":"West","year":"1993","journal-title":"Vaccine"},{"issue":"suppl 1","key":"R35-5-20210202","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"R36-5-20210202","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand Meningococcal B vaccine.","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-200905000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:48:34Z","timestamp":1786038514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-200905000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e318195205e","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}